Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis

Samuel J. Modlin, Tyler Marbach, Jim Werngren, Mikael Mansjö, Sven Hoffner, Faramarz Valafar

Antimicrobial Agents and Chemotherapy · 2021 · 24 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

Pyrazinamide (PZA) is a widely used antitubercular chemotherapeutic. Typically, PZA resistance (PZA-R) emerges in Mycobacterium tuberculosis strains with existing resistance to isoniazid and rifampin (i.e., multidrug resistance [MDR]) and is conferred by loss-of-function pncA mutations that inhibit conversion to its active form, pyrazinoic acid (POA).

References

28